Navigation Links
Intermittent in Biological Technology

deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke

... because atrial fibrillation (AF), a common cardiac arrythmia, is often intermittent and therefore under diagnosed. Detecting AF frequently requires more ... to estimate that 20-30% of these subtypes is likely due to undiagnosed, intermittent AF. This means that AF causes an even larger proportion of stroke than ...

AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia

... AEterna Zentaris. This first efficacy study, titled "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", will assess an intermittent dosage regimen of cetrorelix as a safe and tolerable treatment providing ...

Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer

... drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... of Orchiectomy II-35 Time to Start Hormonal Therapy II-35 Strategies to Enhance Hormonal Treatment II-36 Combination Therapy II-36 intermittent Therapy II-36 Radiation Therapy II-36 Brachytherapy II-36 Treatment Procedure II-37 Benefits of Brachytherapy II-38 Drawbacks of ...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

... study (041) titled, "Cetrorelix pamoate in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study", will assess an intermittent dosage regimen of cetrorelix pamoate as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. ...

Alexza's Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida

... 2008, the company commenced a Phase I/II dose-range-finding, safety and efficacy study of TSC in peripheral arterial disease patients suffering from intermittent claudication. In early 2009, the company will initiate a Phase I proof-of-mechanism trial in patients with high-grade glioma at Johns Hopkins ...

Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program

... The unique activity profile of 2NTX-99 suggests potential utility in a range of atherosclerotic, thrombotic, and microvascular diseases, including intermittent claudication, diabetic nephropathy and pulmonary arterial hypertension. About Nile Therapeutics Nile Therapeutics, Inc. is a clinical-stage ...

AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development

... combination products." AcelRx Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions, with an initial emphasis on pain management. ...

New small-scale generator produces alternating current by stretching zinc oxide wires

... Nanotechnology Excellence. Earlier nanowire nanogenerators and microfiber nanogenerators developed by Wang and his research team depended on intermittent contact between vertically-grown zinc oxide nanowires and an electrode, or the mechanical scrubbing of nanowire-covered fibers. These devices were ...

Wall Street Journal Highlights Blood Management, Strategic Healthcare Group LLC, and Dr. Timothy Hannon

... and the medical community about blood management as a way to improve the efficiency and quality of care simultaneously." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...

Alexion Reports Third Quarter 2008 Results

... recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria). Soliris, or eculizumab, is the only treatment that blocks this hemolysis. About Alexion Alexion ...

American Red Cross Expands Agreement for Strategic Blood Management(TM) Services from Strategic Healthcare Group LLC

... with our mission to provide the best possible service to our client hospitals and optimal outcomes for their patients." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...

AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

... pamoate in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", involves approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This ...

Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors

... facilities and provide data on its impact on patient care. "Current methods for measuring total hemoglobin are invasive and only offer delayed and intermittent results," stated Joe E. Kiani, Masimo Chairman and CEO. "We look forward to working closely with the first customers of our noninvasive hemoglobin ...

Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

Derma Sciences Reports Second Quarter 2008 Results

... ahead. XTRASORB(TM), our new super-absorbent dressing (which complements the MEDIHONEY products) is due out in September, MOBILITY1(TM), our portable intermittent compression device, will be available in October, and we are in the final phase of preparing to launch a novel off-loading device for diabetic foot ...

Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout

... crystals in and around the connective tissue of the joints and in the kidneys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). While gout is a treatable condition, there are limited treatment options, and ...

Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors

... proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit ...

AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal

... a short course therapy with cetrorelix. The improvement lasted well beyond the dosing period. This should, therefore, allow for the development of intermittent dosage regimens of cetrorelix with two or three treatment courses per year, thus relieving concerns about treatment compliance with drugs requiring ...

Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan

... two formulations of cetrorelix to determine the extent and duration of symptomatic improvement and to select the interval between courses for an intermittent treatment scheme. Trial Design Trial-A compared 3 regimens of subcutaneous cetrorelix acetate with placebo (35 patients/group): 5mg x 4, 7 days ...

Alexion Reports First Quarter 2008 Results

... recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria). Soliris, or eculizumab, is the only treatment that blocks this hemolysis. About Alexion ...

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled 'Bipolar Trans Carotenoid Salts and Their Uses,' for Its Family of First-In-Class Molecules

... proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit ...

Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia

... in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", will involve approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This ...

Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Amsterdam Molecular Therapeutics Reports Full Year Results 2007

... - Pre-registration trial in Canada on track - Appointment of Ferdinand Verdonck as chairman of supervisory board. - Global rights for acute intermittent porphyria treatment - Exclusive license to all gene therapy products from CIMA - Agreement with CIMA/Digna Biotech for AAV-mediated IGF-I ...

Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter

... for revenue recognition have now been met. Also includes a $200,000 fee paid by Hollister for marketing rights to our hydorphilic intermittent catheter in September 2003. The fee paid by Hollister was fully recognized in December 2006. This adjustment reduces net income related ...

Alexza's Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference

... Alexza is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexza's Corporate Presentation

... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America

... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics

... higher than the estimated efficacious human dose. Clinical trials will begin in 2008 in peripheral vascular disease patients suffering from intermittent claudication and in cancer patients undergoing radiation therapy. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, ...

Alexza Elects Dr. Hal V. Barron to Its Board of Directors

... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
Other Contents
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
(Date:7/5/2015)... ... July 06, 2015 , ... City Sports, the Boston-based specialty sporting ... two training clinics for first-time triathletes this summer with ethos, the owner and operator ... Thursday, July 9, at 6:00 p.m. at the North End Greenway. The event will ...
(Date:7/5/2015)... ... 2015 , ... Women's Excellence in Wellness, powered by Movestrong announces ... are geared towards families that want their children to stay active as well as ... class will take place TUESDAYS at 4:30pm. Questions? Call 248-601-6683. Women’s Excellence in ...
(Date:7/5/2015)... (PRWEB) , ... July 05, 2015 , ... ... patented products, announces the Weed Master, a landscaping invention that effectively removes ... $75 billion US dollars," says Scott Cooper, CEO and Creative Director of World ...
(Date:7/5/2015)... ... July 05, 2015 , ... Women’s Excellence in Wellness, powered by ... location. The special consists of 2 months of unlimited classes for just $65. Student ... located at 1410 South Lapeer Road in Lake Orion. , Women’s ...
(Date:7/5/2015)... (PRWEB) , ... July 05, 2015 , ... Doctors at ... a new IMRT/surgery combination may one day change the outlook for people with pleural ... it now. , Researchers report that five mesothelioma patients treated with 25Gy ...
Breaking Medicine News(10 mins):Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 4Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 5Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2
Other TagsOther Tags